Really cool study, not limited by the hematologic toxicity we have seen with other CD47 agents

Katherine Zhou@katherinezhoumd.bsky.social · 2y ago

20/31 #TumorBoardTuesday 🏫Mini Tutorial 17🏫 5) Phase 1/2, PT886 (CD47 x CLDN18.2 bispecific) in adv gastric/GEJ or PC (TWINPEAK, NCT05482893) Promotes ADCC by NK cells, phagocytosis by macrophages Part C, cohort 2: 1L adv PDAC w/ CLDN18.2 ≥2+ ≥10%, PT886 + chemo Results pending

This was not an easy study to execute, in patients who have few other (if any) treatment options. Here we can appreciate the monotherapy activity with a BiTE over a mAb.

Katherine Zhou@katherinezhoumd.bsky.social · 2y ago

18/31 #TumorBoardTuesday 🏫Mini Tutorial 15🏫 Efficacy for 600 µg/kg in CLDN18.2 IHC 2+/3+ ≥10%: 27 pts, 8 PRs, 11 SDs, ORR 39.6%, DCR 70.4% DOR and PFS not reached

Bispecifics are so in right now. Learn more about them in this recent review: www.nature.com/articles/s41... But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity

The present and future of bispecific antibodies for cancer therapy - Nature Reviews Drug Discovery

Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent developments in the field of bsAbs for cancer ...

nature.com

Katherine Zhou@katherinezhoumd.bsky.social · 2y ago

15/31 #TumorBoardTuesday 🏫Mini Tutorial 12🏫 CLDN18.2 bispecific trials: 1) Phase 1, Q-1802 (PD-L1 x CLDN18.2) (NCT04856150) 17 pts w/ adv gastric, PC, or BTC, mostly ≥3 prior lines 2/9 PRs, 4/9 SDs AEs: n/v, abd pain, GERD 24.1% G3 TRAEs doi.org/10.1200/JCO.2023.41.4_suppl.382

#TumorBoardTuesday 🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓ 📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer RT and bring others into the discussion‼️